An Open Label Long Term Follow up Study for Patients With Melanoma Who Were Previously Enrolled in the Phase I Study IMM-101-001

Trial Profile

An Open Label Long Term Follow up Study for Patients With Melanoma Who Were Previously Enrolled in the Phase I Study IMM-101-001

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs IMM 101 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Immodulon Therapeutics
  • Most Recent Events

    • 04 Mar 2017 Planned End Date changed from 1 Feb 2016 to 1 Mar 2019.
    • 04 Mar 2017 Planned primary completion date changed from 1 Feb 2016 to 1 Dec 2018.
    • 05 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top